Abstract

BackgroundZinc (Zn) hyper-accumulates in breast tumors and malignant cell lines compared to normal mammary epithelium. The mechanisms responsible for Zn accumulation and the consequence of Zn dysregulation are poorly understood.MethodsMicroarrays were performed to assess differences in the expression of Zn transporters and metallothioneins (MTs) in human breast tumors and breast cancer cell lines. Real-time PCR and immunoblotting were employed to profile Zn transporter expression in representative luminal (T47D), basal (MDA-MB-231), and non-malignant (MCF10A) cell lines. Zn distribution in human tumors was assessed by X-ray fluorescence imaging. Zn distribution and content in cell lines was measured using FluoZin-3 imaging, and quantification and atomic absorption spectroscopy. Functional consequences of ZnT2 over-expression in MDA-MB-231 cells including invasion, proliferation, and cell cycle were measured using Boyden chambers, MTT assays, and flow cytometry, respectively.ResultsGene expression profiling of human breast tumors and breast cancer cell lines identified subtype-specific dysregulation in the Zn transporting network. X-ray fluorescence imaging of breast tumor tissues revealed Zn hyper-accumulation at the margins of Luminal breast tumors while Zn was more evenly distributed within Basal tumors. While both T47D and MDA-MB-231 cells hyper-accumulated Zn relative to MCF10A cells, T47D cells accumulated 2.5-fold more Zn compared to MDA-MB-231 cells. FluoZin-3 imaging indicated that Zn was sequestered into numerous large vesicles in T47D cells, but was retained in the cytoplasm and found in fewer and larger, amorphous sub-cellular compartments in MDA-MB-231 cells. The differences in Zn localization mirrored the relative abundance of the Zn transporter ZnT2; T47D cells over-expressed ZnT2, whereas MDA-MB-231 cells did not express ZnT2 protein due to proteasomal degradation. To determine the functional relevance of the lack of ZnT2 in MDA-MB-231cells, cells were transfected to express ZnT2. ZnT2 over-expression led to Zn vesicularization, shifts in cell cycle, enhanced apoptosis, and reduced proliferation and invasion.ConclusionsThis comprehensive analysis of the Zn transporting network in malignant breast tumors and cell lines illustrates that distinct subtype-specific dysregulation of Zn management may underlie phenotypic characteristics of breast cancers such as grade, invasiveness, metastatic potential, and response to therapy.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-015-0486-y) contains supplementary material, which is available to authorized users.

Highlights

  • Zinc (Zn) hyper-accumulates in breast tumors and malignant cell lines compared to normal mammary epithelium

  • Zn transporter expression differs between Luminal and Basal tumors Due to the differences in Zn distribution, we postulated that Basal and Luminal breast tumors would have unique patterns of Zn transporter expression

  • Pair-wise comparison of the subtypes show that Basal and estrogen receptor (ER)+ tumors had a distinct pattern of SLC30A, SLC39A, and MT gene expression

Read more

Summary

Introduction

Zinc (Zn) hyper-accumulates in breast tumors and malignant cell lines compared to normal mammary epithelium. Four subtypes based on expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) are recognized including: Luminal A (ER+/PR+/HER2−), Luminal B (ER+/PR+/HER2+), Basal (ER−/PR−/HER2−) and HER2- enriched (ER−/PR−/HER2+). These subtypes differ in incidence [1], aggressiveness, and response to therapy [2, 3]. It has been reported that breast tumors accumulate zinc (Zn) to levels well above those observed in normal tissue [4]. The mechanisms responsible for Zn accumulation, and the relationship between Zn accumulation and breast cancer subtype are not understood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call